Recurrent Glioblastoma, IDH-Wildtype Clinical Trials

16 clinical trials for Recurrent Glioblastoma, IDH-Wildtype across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma — RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment — RECRUITING · PHASE1
• Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas — RECRUITING · PHASE1
• ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial — RECRUITING · PHASE1
• [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma — RECRUITING · PHASE1
• Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma — RECRUITING · PHASE1
• Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma — RECRUITING · PHASE1
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma — RECRUITING · PHASE2
• Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy — RECRUITING · PHASE1
• A Clinical Trial of P134 Cells in Recurrent Glioblastoma — RECRUITING · PHASE1
• Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma — RECRUITING · PHASE2
• D2C7-IT + 2141-V11 Combination Post-resection in rGBM — RECRUITING · PHASE1
• Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma — NOT_YET_RECRUITING · PHASE1
• Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma — NOT_YET_RECRUITING · PHASE1
• Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma — NOT_YET_RECRUITING · PHASE2
• Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma — WITHDRAWN · PHASE2

Refine this search